Identification
NameNafamostat
Accession NumberDB12598
TypeSmall Molecule
GroupsApproved, Investigational
Description

Nafamostat is a synthetic serine protease inhibitor that is commonly formulated with hydrochloric acid due to its basic properties. It has been used in trials studying the prevention of Liver Transplantation and Postreperfusion Syndrome. The use of nafamostat in Asian countries is approved as an anticoagulant therapy for patients undergoing continuous renal replacement therapy due to acute kidney injury.

Structure
Thumb
Synonyms
FUT-175
Nafamostat dimethanesulfonate
Nafamostat mesilate
External IDs Not Available
Product Ingredients
IngredientUNIICASInChI KeyDetails
Nafamostat mesylate1D2T74921W 82956-11-4ZESSXQLDESEKGC-UHFFFAOYSA-NDetails
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
BerabuTobishi Pharmaceutical, Japan
BuipelTeva Seiyaku, Japan
BuseronSawai Seiyaku, Japan
CoahibitorAY Pharma, Japan
FamosetTowa Yakuhin, Japan
FuthanTorii Yakuhin, Japan
NafastonFuji Seiyaku, Japan
NafatatNichi-Iko Pharmaceutical, Japan
NamostattPola Pharma, Japan
NaotaminAsahi Kasei Pharma, Japan
OpsunSanwa Kagaku, Japan
PathronNipro, Japan
RonastatKoa Isei, Japan
Brand mixturesNot Available
Categories
UNIIY25LQ0H97D
CAS number81525-10-2
WeightAverage: 347.378
Monoisotopic: 347.138224807
Chemical FormulaC19H17N5O2
InChI KeyMQQNFDZXWVTQEH-UHFFFAOYSA-N
InChI
InChI=1S/C19H17N5O2/c20-17(21)14-2-1-13-10-16(8-5-12(13)9-14)26-18(25)11-3-6-15(7-4-11)24-19(22)23/h1-10H,(H3,20,21)(H4,22,23,24)
IUPAC Name
6-carbamimidoylnaphthalen-2-yl 4-carbamimidamidobenzoate
SMILES
NC(=N)NC1=CC=C(C=C1)C(=O)OC1=CC=C2C=C(C=CC2=C1)C(N)=N
Pharmacology
Indication

Used as an anticoagulant in patients with disseminative blood vessel coagulation, hemorrhagic lesions, and hemorrhagic tendencies. It prevents blood clot formation during extracorporeal circulation in patients undergoing continuous renal replacement therapy and extra corporeal membrane oxygenation.

Structured Indications Not Available
Pharmacodynamics

Nafamostat is a fast-acting proteolytic inhibitor used during hemodialysis to prevent the proteolysis of fibrinogen into fibrin by competitively inhibiting several serine proteases including thrombin. It improves acute pancreatitis and prevents blood clot formation during extracorporeal circulation and has an anti-inflammatory effect in vitro. A study suggets that nafamostat has a neuroprotective role during ischemia-induced brain injury from antithrombin activity [5].

Mechanism of action

Nafamostat mesilate inhibits various enzyme systems, such as coagulation and fibrinolytic systems (thrombin, Xa, and XIIa), the kallikrein–kinin system, the complement system, pancreatic proteases and activation of protease-activated receptors (PARs) [6]. Nafamostat inhibits lipopolysaccharide-induced nitric oxide production, apoptosis, and interleukin (IL)-6 and IL-8 levels in cultured human trophoblasts. It is shown to act as an antioxidant in TNF-α-induced ROS production [2].

TargetKindPharmacological actionActionsOrganismUniProt ID
ProthrombinProteinyes
inhibitor
HumanP00734 details
Coagulation factor XProteinyes
inhibitor
HumanP00742 details
Coagulation factor XIIProteinyes
inhibitor
HumanP00748 details
Trypsin-1Proteinyes
inhibitor
HumanP07477 details
Kallikrein-1Proteinyes
inhibitor
HumanP06870 details
Intercellular adhesion molecule 1Proteinunknown
inhibitor
HumanP05362 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Nafamostat is mainly hydrolyzed by hepatic carboxyesterase and long-chain acyl-CoA hydrolase in human liver cytosol. Main metabolites are p-guanidinobenzoic acid (PGBA) and 6-amidino-2-naphthol (AN) as inactive protease inhibitors.

Route of elimination

Two metabolites of NM, p-guanidinobenzoic acid (PGBA) and 6-amidino-2-naphthol (AN), are renally excreted. Nafamostat accumulates in the kidneys.

Half life

Approximately 8 minutes [4]

ClearanceNot Available
Toxicity

Reported incidences of agranulocytosis, hyperkalemia, and anaphylaxis. The use of nafamostat has been reported to cause cardiac arrest in patients receiving dialysis due to a sudden change in the patient's condition such as dyspnea. A study suggests that the drug and its metabolites may inhibit the amiloride-sensitive sodium (Na) conductance at the collecting ducts, resulting in an inhibition of K secretion and hyperkalemia [7]. Reported LD50 value from intravenous administration in rats is 16.4mg/kg.

Affected organismsNot Available
PathwaysNot Available
Pharmacogenomic Effects/ADRs Not Available
Interactions
Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Nafamostat is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Nafamostat is combined with 19-norandrostenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Nafamostat is combined with 5-androstenedione.Experimental, Illicit
AbacavirThe serum concentration of Abacavir can be decreased when it is combined with Nafamostat.Approved, Investigational
AbciximabNafamostat may increase the anticoagulant activities of Abciximab.Approved
AcebutololNafamostat may decrease the antihypertensive activities of Acebutolol.Approved
AceclofenacAceclofenac may increase the anticoagulant activities of Nafamostat.Approved
AcenocoumarolNafamostat may increase the anticoagulant activities of Acenocoumarol.Approved
Acetylsalicylic acidAcetylsalicylic acid may increase the anticoagulant activities of Nafamostat.Approved, Vet Approved
AclarubicinNafamostat may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational
AdapaleneAdapalene may increase the anticoagulant activities of Nafamostat.Approved
AlclometasoneThe risk or severity of adverse effects can be increased when Nafamostat is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Nafamostat is combined with Aldosterone.Experimental
Alendronic acidThe risk or severity of adverse effects can be increased when Nafamostat is combined with Alendronic acid.Approved
AlfuzosinThe serum concentration of Alfuzosin can be increased when it is combined with Nafamostat.Approved, Investigational
AliskirenNafamostat may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AllylestrenolThe therapeutic efficacy of Nafamostat can be decreased when used in combination with Allylestrenol.Approved
AlprazolamThe serum concentration of Alprazolam can be increased when it is combined with Nafamostat.Approved, Illicit, Investigational
AlprenololNafamostat may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Nafamostat.Approved, Investigational
AlteplaseAlteplase may increase the anticoagulant activities of Nafamostat.Approved
Ambroxol acefyllinateThe serum concentration of Ambroxol acefyllinate can be decreased when it is combined with Nafamostat.Experimental
AmcinonideThe risk or severity of adverse effects can be increased when Nafamostat is combined with Amcinonide.Approved
AmikacinNafamostat may decrease the excretion rate of Amikacin which could result in a higher serum level.Approved, Vet Approved
AmilorideNafamostat may decrease the antihypertensive activities of Amiloride.Approved
AmineptineThe serum concentration of Amineptine can be increased when it is combined with Nafamostat.Illicit, Withdrawn
AminophyllineThe serum concentration of Aminophylline can be decreased when it is combined with Nafamostat.Approved
Aminosalicylic AcidAminosalicylic Acid may increase the anticoagulant activities of Nafamostat.Approved
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Nafamostat.Approved
AmrubicinNafamostat may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
AnagrelideAnagrelide may increase the anticoagulant activities of Nafamostat.Approved
AncrodNafamostat may increase the anticoagulant activities of Ancrod.Investigational
AndrographolideHMPL-004 may increase the anticoagulant activities of Nafamostat.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Nafamostat is combined with 4-Androstenedione.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Nafamostat is combined with Anecortave.Investigational
AnisodamineAnisodamine may increase the anticoagulant activities of Nafamostat.Investigational
AnistreplaseAnistreplase may increase the anticoagulant activities of Nafamostat.Approved
AntipyrineAntipyrine may increase the anticoagulant activities of Nafamostat.Approved
Antithrombin III humanNafamostat may increase the anticoagulant activities of Antithrombin III human.Approved
ApixabanApixaban may increase the anticoagulant activities of Nafamostat.Approved
ApocyninAcetovanillone may increase the anticoagulant activities of Nafamostat.Investigational
ApramycinNafamostat may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastApremilast may increase the anticoagulant activities of Nafamostat.Approved, Investigational
ArbekacinNafamostat may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved
ArdeparinNafamostat may increase the anticoagulant activities of Ardeparin.Approved, Withdrawn
ArgatrobanNafamostat may increase the anticoagulant activities of Argatroban.Approved, Investigational
ArotinololNafamostat may decrease the antihypertensive activities of Arotinolol.Approved
AtenololNafamostat may decrease the antihypertensive activities of Atenolol.Approved
AtorvastatinThe serum concentration of Atorvastatin can be increased when it is combined with Nafamostat.Approved
AzapropazoneAzapropazone may increase the anticoagulant activities of Nafamostat.Withdrawn
AzelastineAzelastine may increase the anticoagulant activities of Nafamostat.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Nafamostat.Approved
BalsalazideNafamostat may increase the nephrotoxic activities of Balsalazide.Approved, Investigational
BazedoxifeneBazedoxifene may decrease the anticoagulant activities of Nafamostat.Approved, Investigational
BCG vaccineThe therapeutic efficacy of Bcg can be decreased when used in combination with Nafamostat.Investigational
BecaplerminNafamostat may increase the anticoagulant activities of Becaplermin.Approved, Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Nafamostat is combined with Beclomethasone dipropionate.Approved, Investigational
BefunololNafamostat may decrease the antihypertensive activities of Befunolol.Experimental
BemiparinBemiparin may increase the anticoagulant activities of Nafamostat.Approved
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Nafamostat.Approved, Investigational
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Nafamostat.Approved
BenoxaprofenBenoxaprofen may increase the anticoagulant activities of Nafamostat.Withdrawn
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with Nafamostat.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Nafamostat is combined with Betamethasone.Approved, Vet Approved
BetaxololNafamostat may decrease the antihypertensive activities of Betaxolol.Approved
Betulinic AcidBetulinic Acid may increase the anticoagulant activities of Nafamostat.Investigational
BevantololNafamostat may decrease the antihypertensive activities of Bevantolol.Approved
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Nafamostat.Approved, Investigational
BisoprololNafamostat may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinNafamostat may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BoceprevirThe serum concentration of Nafamostat can be decreased when it is combined with Boceprevir.Withdrawn
BopindololNafamostat may decrease the antihypertensive activities of Bopindolol.Approved
BromfenacBromfenac may increase the anticoagulant activities of Nafamostat.Approved
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Nafamostat.Approved, Investigational
BucillamineBucillamine may increase the anticoagulant activities of Nafamostat.Investigational
BucindololNafamostat may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Nafamostat is combined with Budesonide.Approved
BufuralolNafamostat may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumetanideNafamostat may decrease the diuretic activities of Bumetanide.Approved
BupranololNafamostat may decrease the antihypertensive activities of Bupranolol.Approved
ButylphthalideButylphthalide may increase the anticoagulant activities of Nafamostat.Investigational
CabergolineThe serum concentration of Cabergoline can be increased when it is combined with Nafamostat.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Nafamostat.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Nafamostat.Experimental
CangrelorCangrelor may increase the anticoagulant activities of Nafamostat.Approved
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Nafamostat.Approved
CarbamazepineThe metabolism of Nafamostat can be increased when combined with Carbamazepine.Approved, Investigational
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Nafamostat.Approved
CarprofenCarprofen may increase the anticoagulant activities of Nafamostat.Approved, Vet Approved, Withdrawn
CarteololNafamostat may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolNafamostat may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
CastanospermineCastanospermine may increase the anticoagulant activities of Nafamostat.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Nafamostat is combined with Celecoxib.Approved, Investigational
CeliprololNafamostat may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CertoparinNafamostat may increase the anticoagulant activities of Certoparin.Approved
ChloroquineChloroquine may increase the anticoagulant activities of Nafamostat.Approved, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Nafamostat.Approved, Vet Approved
ChlorotrianiseneThe serum concentration of Chlorotrianisene can be decreased when it is combined with Nafamostat.Withdrawn
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Nafamostat.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Nafamostat resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Choline magnesium trisalicylateTrisalicylate-choline may increase the anticoagulant activities of Nafamostat.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Nafamostat is combined with Ciclesonide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Nafamostat.Approved
CilostazolCilostazol may increase the anticoagulant activities of Nafamostat.Approved
CinoxacinNafamostat may increase the neuroexcitatory activities of Cinoxacin.Approved, Withdrawn
CiprofloxacinNafamostat may increase the neuroexcitatory activities of Ciprofloxacin.Approved, Investigational
CisaprideThe serum concentration of Cisapride can be increased when it is combined with Nafamostat.Approved, Investigational, Withdrawn
Citric AcidNafamostat may increase the anticoagulant activities of Citric Acid.Nutraceutical, Vet Approved
ClarithromycinThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Nafamostat.Approved
ClobetasolThe risk or severity of adverse effects can be increased when Nafamostat is combined with Clobetasol.Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Nafamostat is combined with Clobetasol propionate.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Nafamostat is combined with Clocortolone.Approved
Clodronic AcidThe risk or severity of adverse effects can be increased when Nafamostat is combined with Clodronate.Approved, Investigational, Vet Approved
ClomipramineThe serum concentration of Clomipramine can be increased when it is combined with Nafamostat.Approved, Vet Approved
ClonixinClonixin may increase the anticoagulant activities of Nafamostat.Approved
ClopidogrelClopidogrel may increase the anticoagulant activities of Nafamostat.Approved, Nutraceutical
ColesevelamColesevelam can cause a decrease in the absorption of Nafamostat resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Nafamostat resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Conjugated estrogensThe serum concentration of Conjugated Equine Estrogens can be decreased when it is combined with Nafamostat.Approved
Cortisone acetateThe risk or severity of adverse effects can be increased when Nafamostat is combined with Cortisone acetate.Approved
CurcuminCurcumin may increase the anticoagulant activities of Nafamostat.Investigational
CyclobenzaprineThe serum concentration of Cyclobenzaprine can be increased when it is combined with Nafamostat.Approved
CyclophosphamideThe risk or severity of adverse effects can be increased when Nafamostat is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Nafamostat.Approved, Investigational, Vet Approved
Dabigatran etexilateDabigatran etexilate may increase the anticoagulant activities of Nafamostat.Approved
DalteparinNafamostat may increase the anticoagulant activities of Dalteparin.Approved
DarexabanNafamostat may increase the anticoagulant activities of Ym150.Investigational
DasatinibDasatinib may increase the anticoagulant activities of Nafamostat.Approved, Investigational
DaunorubicinNafamostat may decrease the excretion rate of Daunorubicin which could result in a higher serum level.Approved
DeferasiroxThe risk or severity of adverse effects can be increased when Nafamostat is combined with Deferasirox.Approved, Investigational
DefibrotideDefibrotide may increase the anticoagulant activities of Nafamostat.Approved, Investigational
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Nafamostat.Approved
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Nafamostat.Approved
Deoxycholic AcidThe risk or severity of adverse effects can be increased when Nafamostat is combined with Deoxycholic Acid.Approved
DesipramineThe serum concentration of Desipramine can be increased when it is combined with Nafamostat.Approved
DesirudinNafamostat may increase the anticoagulant activities of Desirudin.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Nafamostat is combined with Desmopressin.Approved
DesmoteplaseDesmoteplase may increase the anticoagulant activities of Nafamostat.Investigational
DesogestrelThe therapeutic efficacy of Nafamostat can be decreased when used in combination with Desogestrel.Approved
DesoximetasoneThe risk or severity of adverse effects can be increased when Nafamostat is combined with Desoximetasone.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Nafamostat is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Nafamostat is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Nafamostat.Approved
DextranNafamostat may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Nafamostat may increase the anticoagulant activities of Dextran 40.Approved
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Nafamostat.Approved, Vet Approved
DiclofenacDiclofenac may increase the anticoagulant activities of Nafamostat.Approved, Vet Approved
DicoumarolNafamostat may increase the anticoagulant activities of Dicoumarol.Approved
DienestrolThe serum concentration of Dienestrol can be decreased when it is combined with Nafamostat.Approved
DienogestThe therapeutic efficacy of Nafamostat can be decreased when used in combination with Dienogest.Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Nafamostat.Approved
DiflorasoneThe risk or severity of adverse effects can be increased when Nafamostat is combined with Diflorasone.Approved
DiflunisalDiflunisal may increase the anticoagulant activities of Nafamostat.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Nafamostat is combined with Difluocortolone.Approved
DifluprednateThe risk or severity of adverse effects can be increased when Nafamostat is combined with Difluprednate.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Nafamostat.Approved
DihydroergotamineThe serum concentration of Dihydroergotamine can be increased when it is combined with Nafamostat.Approved
DiltiazemThe metabolism of Diltiazem can be decreased when combined with Nafamostat.Approved
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Nafamostat.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Nafamostat.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Nafamostat.Approved
DipyridamoleDipyridamole may increase the anticoagulant activities of Nafamostat.Approved
DitazoleDitazole may increase the anticoagulant activities of Nafamostat.Approved, Withdrawn
DosulepinThe serum concentration of Dosulepin can be increased when it is combined with Nafamostat.Approved
DoxepinThe serum concentration of Doxepin can be increased when it is combined with Nafamostat.Approved
DoxorubicinNafamostat may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved, Investigational
DrospirenoneNafamostat may increase the hyperkalemic activities of Drospirenone.Approved
Drotrecogin alfaDrotrecogin alfa may increase the anticoagulant activities of Nafamostat.Approved, Investigational, Withdrawn
DroxicamDroxicam may increase the anticoagulant activities of Nafamostat.Approved
DuvelisibDuvelisib may increase the anticoagulant activities of Nafamostat.Investigational
DydrogesteroneThe therapeutic efficacy of Nafamostat can be decreased when used in combination with Dydrogesterone.Approved, Withdrawn
DyphyllineThe serum concentration of Dyphylline can be decreased when it is combined with Nafamostat.Approved
E-6201E6201 may increase the anticoagulant activities of Nafamostat.Investigational
EbselenEbselen may increase the anticoagulant activities of Nafamostat.Investigational
Edetic AcidNafamostat may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanEdoxaban may increase the anticoagulant activities of Nafamostat.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Nafamostat.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Nafamostat.Approved
EnfuvirtideThe serum concentration of Enfuvirtide can be increased when it is combined with Nafamostat.Approved, Investigational
EnoxacinNafamostat may increase the neuroexcitatory activities of Enoxacin.Approved
EnoxaparinNafamostat may increase the anticoagulant activities of Enoxaparin.Approved
EpinastineEpinastine may increase the anticoagulant activities of Nafamostat.Approved, Investigational
EpirizoleEpirizole may increase the anticoagulant activities of Nafamostat.Approved
EpirubicinNafamostat may decrease the excretion rate of Epirubicin which could result in a higher serum level.Approved
EplerenoneNafamostat may decrease the antihypertensive activities of Eplerenone.Approved
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Nafamostat.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Nafamostat.Approved
EptifibatideEptifibatide may increase the anticoagulant activities of Nafamostat.Approved, Investigational
EquileninThe risk or severity of adverse effects can be increased when Nafamostat is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Nafamostat is combined with Equilin.Approved
EquolS Equol may decrease the anticoagulant activities of Nafamostat.Investigational
Ergoloid mesylateThe serum concentration of Ergoloid mesylate can be increased when it is combined with Nafamostat.Approved
ErgonovineThe serum concentration of Ergonovine can be increased when it is combined with Nafamostat.Approved
ErgotamineThe serum concentration of Ergotamine can be increased when it is combined with Nafamostat.Approved
EsmirtazapineThe serum concentration of Esmirtazapine can be increased when it is combined with Nafamostat.Investigational
EsmololNafamostat may decrease the antihypertensive activities of Esmolol.Approved
EstradiolThe serum concentration of Estradiol can be decreased when it is combined with Nafamostat.Approved, Investigational, Vet Approved
EstramustineThe serum concentration of Estramustine can be decreased when it is combined with Nafamostat.Approved
EstriolEstriol may decrease the anticoagulant activities of Nafamostat.Approved, Vet Approved
Estrogens, esterifiedThe serum concentration of Estrogens, esterified can be decreased when it is combined with Nafamostat.Approved
EstroneEstrone may decrease the anticoagulant activities of Nafamostat.Approved
Estrone sulfateThe serum concentration of Estrone sulfate can be decreased when it is combined with Nafamostat.Approved
Etacrynic acidNafamostat may decrease the diuretic activities of Etacrynic acid.Approved
EtanerceptEtanercept may increase the anticoagulant activities of Nafamostat.Approved, Investigational
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Nafamostat.Approved
Ethyl biscoumacetateNafamostat may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Ethynodiol diacetateThe therapeutic efficacy of Nafamostat can be decreased when used in combination with Ethynodiol diacetate.Approved
Etidronic acidThe risk or severity of adverse effects can be increased when Nafamostat is combined with Etidronic acid.Approved
EtodolacThe risk or severity of adverse effects can be increased when Nafamostat is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may increase the anticoagulant activities of Nafamostat.Approved
EtonogestrelThe therapeutic efficacy of Nafamostat can be decreased when used in combination with Etonogestrel.Approved, Investigational
EtoricoxibThe risk or severity of adverse effects can be increased when Nafamostat is combined with Etoricoxib.Approved, Investigational
EtravirineThe serum concentration of Etravirine can be decreased when it is combined with Nafamostat.Approved
FenbufenFenbufen may increase the anticoagulant activities of Nafamostat.Approved
FenoprofenFenoprofen may increase the anticoagulant activities of Nafamostat.Approved
FibrinolysinPlasmin may increase the anticoagulant activities of Nafamostat.Investigational
FingolimodNafamostat may increase the immunosuppressive activities of Fingolimod.Approved, Investigational
FleroxacinNafamostat may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Nafamostat.Approved, Withdrawn
FludrocortisoneThe risk or severity of adverse effects can be increased when Nafamostat is combined with Fludrocortisone.Approved
FluindioneNafamostat may increase the anticoagulant activities of Fluindione.Investigational
FlumequineNafamostat may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Nafamostat is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Nafamostat is combined with Flunisolide.Approved, Investigational
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Nafamostat is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Nafamostat is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Nafamostat is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Nafamostat is combined with Fluorometholone.Approved
FluprednideneThe risk or severity of adverse effects can be increased when Nafamostat is combined with Fluprednidene.Approved, Withdrawn
FlurandrenolideThe risk or severity of adverse effects can be increased when Nafamostat is combined with Flurandrenolide.Approved
FlurbiprofenFlurbiprofen may increase the anticoagulant activities of Nafamostat.Approved, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Nafamostat is combined with Fluticasone furoate.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Nafamostat is combined with Fluticasone Propionate.Approved
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Nafamostat.Approved, Nutraceutical, Vet Approved
FondaparinuxNafamostat may increase the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumNafamostat may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Nafamostat.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Nafamostat is combined with Formestane.Approved, Investigational, Withdrawn
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Nafamostat.Approved
FramycetinNafamostat may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemideNafamostat may decrease the diuretic activities of Furosemide.Approved, Vet Approved
G17DTThe risk or severity of adverse effects can be increased when Nafamostat is combined with G17DT.Investigational
GabexateNafamostat may increase the anticoagulant activities of Gabexate.Investigational
GatifloxacinNafamostat may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Nafamostat.Approved, Withdrawn
GemifloxacinNafamostat may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinNafamostat may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GenisteinGenistein may decrease the anticoagulant activities of Nafamostat.Investigational
GentamicinNafamostat may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1ANafamostat may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GestodeneThe therapeutic efficacy of Nafamostat can be decreased when used in combination with Gestodene.Approved
GestrinoneThe therapeutic efficacy of Nafamostat can be decreased when used in combination with Gestrinone.Approved
GrepafloxacinNafamostat may increase the neuroexcitatory activities of Grepafloxacin.Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Nafamostat is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when Nafamostat is combined with HE3286.Investigational
HeminHemin may increase the anticoagulant activities of Nafamostat.Approved
HeparinNafamostat may increase the anticoagulant activities of Heparin.Approved, Investigational
HexestrolThe serum concentration of Hexestrol can be decreased when it is combined with Nafamostat.Withdrawn
HigenamineHigenamine may increase the anticoagulant activities of Nafamostat.Investigational
HydralazineNafamostat may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Nafamostat.Approved, Vet Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Nafamostat is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Nafamostat.Approved
Hydroxyprogesterone caproateThe therapeutic efficacy of Nafamostat can be decreased when used in combination with Hydroxyprogesterone caproate.Approved
IbandronateThe risk or severity of adverse effects can be increased when Nafamostat is combined with Ibandronate.Approved, Investigational
Ibritumomab tiuxetanThe risk or severity of adverse effects can be increased when Nafamostat is combined with Ibritumomab tiuxetan.Approved
IbrutinibThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Nafamostat.Approved
IbudilastIbudilast may increase the anticoagulant activities of Nafamostat.Approved, Investigational
IbuprofenIbuprofen may increase the anticoagulant activities of Nafamostat.Approved
IbuproxamIbuproxam may increase the anticoagulant activities of Nafamostat.Withdrawn
IcatibantIcatibant may increase the anticoagulant activities of Nafamostat.Approved
Icosapent ethylIcosapent ethyl may increase the anticoagulant activities of Nafamostat.Approved, Nutraceutical
IdarubicinNafamostat may decrease the excretion rate of Idarubicin which could result in a higher serum level.Approved
IfenprodilIfenprodil may increase the anticoagulant activities of Nafamostat.Approved, Withdrawn
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Nafamostat.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Nafamostat.Investigational
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Nafamostat.Approved
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Nafamostat.Approved
IndenololNafamostat may decrease the antihypertensive activities of Indenolol.Withdrawn
IndobufenIndobufen may increase the anticoagulant activities of Nafamostat.Investigational
IndomethacinIndomethacin may increase the anticoagulant activities of Nafamostat.Approved, Investigational
IndoprofenIndoprofen may increase the anticoagulant activities of Nafamostat.Withdrawn
INGN 201The risk or severity of adverse effects can be increased when Nafamostat is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when Nafamostat is combined with INGN 225.Investigational
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Nafamostat.Approved, Investigational
IsoxicamIsoxicam may increase the anticoagulant activities of Nafamostat.Withdrawn
KanamycinNafamostat may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Vet Approved
KebuzoneKebuzone may increase the anticoagulant activities of Nafamostat.Experimental
KetanserinKetanserin may increase the anticoagulant activities of Nafamostat.Investigational
KetoprofenKetoprofen may increase the anticoagulant activities of Nafamostat.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Nafamostat.Approved
KetorolacKetorolac may increase the anticoagulant activities of Nafamostat.Approved
LabetalolNafamostat may decrease the antihypertensive activities of Labetalol.Approved
LandiololNafamostat may decrease the antihypertensive activities of Aop200704.Investigational
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Nafamostat.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Nafamostat is combined with Leflunomide.Approved, Investigational
LepirudinNafamostat may increase the anticoagulant activities of Lepirudin.Approved
LevobunololNafamostat may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinNafamostat may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LevonorgestrelThe therapeutic efficacy of Nafamostat can be decreased when used in combination with Levonorgestrel.Approved, Investigational
LimaprostThe risk or severity of adverse effects can be increased when Limaprost is combined with Nafamostat.Approved
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Nafamostat.Approved, Investigational
LisofyllineLisofylline may increase the anticoagulant activities of Nafamostat.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Nafamostat.Approved
LomefloxacinNafamostat may increase the neuroexcitatory activities of Lomefloxacin.Approved
LornoxicamLornoxicam may increase the anticoagulant activities of Nafamostat.Approved
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Nafamostat.Approved
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Nafamostat.Approved, Investigational
LoxoprofenLoxoprofen may increase the anticoagulant activities of Nafamostat.Approved
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Nafamostat.Approved, Investigational
LumiracoxibThe risk or severity of adverse effects can be increased when Nafamostat is combined with Lumiracoxib.Approved, Investigational
LynestrenolThe therapeutic efficacy of Nafamostat can be decreased when used in combination with Lynestrenol.Investigational
Magnesium salicylateMagnesium salicylate may increase the anticoagulant activities of Nafamostat.Approved
MasoprocolMasoprocol may increase the anticoagulant activities of Nafamostat.Approved
ME-609The risk or severity of adverse effects can be increased when Nafamostat is combined with ME-609.Investigational
Meclofenamic acidMeclofenamic acid may increase the anticoagulant activities of Nafamostat.Approved, Vet Approved
MedrogestoneThe therapeutic efficacy of Nafamostat can be decreased when used in combination with Medrogestone.Approved
Medroxyprogesterone acetateThe therapeutic efficacy of Nafamostat can be decreased when used in combination with Medroxyprogesterone acetate.Approved, Investigational
MedrysoneThe risk or severity of adverse effects can be increased when Nafamostat is combined with Medrysone.Approved
Mefenamic acidMefenamic acid may increase the anticoagulant activities of Nafamostat.Approved
Megestrol acetateThe therapeutic efficacy of Nafamostat can be decreased when used in combination with Megestrol acetate.Approved, Vet Approved
MeloxicamMeloxicam may increase the anticoagulant activities of Nafamostat.Approved, Vet Approved
MesalazineNafamostat may increase the nephrotoxic activities of Mesalazine.Approved
MestranolThe serum concentration of Mestranol can be decreased when it is combined with Nafamostat.Approved
MetamizoleMetamizole may increase the anticoagulant activities of Nafamostat.Withdrawn
MethallenestrilThe serum concentration of Methallenestril can be decreased when it is combined with Nafamostat.Experimental
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Nafamostat.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Nafamostat.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Nafamostat is combined with Methylprednisolone.Approved, Vet Approved
MetipranololNafamostat may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Nafamostat.Approved
MetoprololNafamostat may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MetrizamideNafamostat may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Nafamostat.Approved, Illicit
MilrinoneMilrinone may increase the anticoagulant activities of Nafamostat.Approved
MirtazapineThe serum concentration of Mirtazapine can be increased when it is combined with Nafamostat.Approved
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Nafamostat.Approved
MizoribineMizoribine may increase the anticoagulant activities of Nafamostat.Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Nafamostat.Approved
MometasoneThe risk or severity of adverse effects can be increased when Nafamostat is combined with Mometasone.Approved, Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Nafamostat.Approved
MoxifloxacinNafamostat may increase the neuroexcitatory activities of Moxifloxacin.Approved, Investigational
Mycophenolate mofetilMycophenolate mofetil may increase the anticoagulant activities of Nafamostat.Approved, Investigational
Mycophenolic acidMycophenolic acid may increase the anticoagulant activities of Nafamostat.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Nafamostat is combined with Nabumetone.Approved
NadololNafamostat may decrease the antihypertensive activities of Nadolol.Approved
NadroparinNafamostat may increase the anticoagulant activities of Nadroparin.Approved
NaftifineNaftifine may increase the anticoagulant activities of Nafamostat.Approved
NaftopidilNaftopidil may increase the anticoagulant activities of Nafamostat.Investigational
Nalidixic AcidNafamostat may increase the neuroexcitatory activities of Nalidixic Acid.Approved
NaproxenNaproxen may increase the anticoagulant activities of Nafamostat.Approved, Vet Approved
NatalizumabThe risk or severity of adverse effects can be increased when Nafamostat is combined with Natalizumab.Approved, Investigational
NCX 1022The risk or severity of adverse effects can be increased when Nafamostat is combined with NCX 1022.Investigational
NeamineNafamostat may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NefazodoneThe serum concentration of Nefazodone can be increased when it is combined with Nafamostat.Approved, Withdrawn
NeomycinNafamostat may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved
NepafenacNepafenac may increase the anticoagulant activities of Nafamostat.Approved
NetilmicinNafamostat may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved
Niflumic AcidNiflumic Acid may increase the anticoagulant activities of Nafamostat.Approved
NimesulideNimesulide may increase the anticoagulant activities of Nafamostat.Approved, Withdrawn
NintedanibThe risk or severity of adverse effects can be increased when Nafamostat is combined with Nintedanib.Approved
NitroaspirinNitroaspirin may increase the anticoagulant activities of Nafamostat.Investigational
NorethisteroneThe therapeutic efficacy of Nafamostat can be decreased when used in combination with Norethisterone.Approved
NorfloxacinNafamostat may increase the neuroexcitatory activities of Norfloxacin.Approved
NortriptylineThe serum concentration of Nortriptyline can be increased when it is combined with Nafamostat.Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Nafamostat is combined with Obinutuzumab.Approved
OfloxacinNafamostat may increase the neuroexcitatory activities of Ofloxacin.Approved
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Nafamostat is combined with Oleoyl estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Nafamostat.Approved, Investigational
OlopatadineOlopatadine may increase the anticoagulant activities of Nafamostat.Approved
OlsalazineNafamostat may increase the nephrotoxic activities of Olsalazine.Approved
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Nafamostat is combined with Omacetaxine mepesuccinate.Approved
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Nafamostat.Investigational
Omega-3 fatty acidsOmega-3 fatty acids may increase the anticoagulant activities of Nafamostat.Approved, Nutraceutical
OpipramolThe serum concentration of Opipramol can be increased when it is combined with Nafamostat.Investigational
OxaprozinOxaprozin may increase the anticoagulant activities of Nafamostat.Approved
OxprenololNafamostat may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneOxyphenbutazone may increase the anticoagulant activities of Nafamostat.Withdrawn
OzagrelKct 0809 may increase the anticoagulant activities of Nafamostat.Investigational
PamidronateThe risk or severity of adverse effects can be increased when Nafamostat is combined with Pamidronate.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Nafamostat is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Nafamostat is combined with Parecoxib.Approved
ParnaparinParnaparin may increase the anticoagulant activities of Nafamostat.Approved
ParomomycinNafamostat may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
PazufloxacinNafamostat may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinNafamostat may increase the neuroexcitatory activities of Pefloxacin.Approved
PenbutololNafamostat may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
Pentosan PolysulfatePentosan Polysulfate may increase the anticoagulant activities of Nafamostat.Approved
PentoxifyllinePentoxifylline may increase the anticoagulant activities of Nafamostat.Approved, Investigational
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Nafamostat.Approved
PethidineThe risk or severity of adverse effects can be increased when Nafamostat is combined with Pethidine.Approved
PhenindioneNafamostat may increase the anticoagulant activities of Phenindione.Approved
PhenprocoumonNafamostat may increase the anticoagulant activities of Phenprocoumon.Approved
PhenylbutazonePhenylbutazone may increase the anticoagulant activities of Nafamostat.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Nafamostat.Approved, Investigational
PimozideThe serum concentration of Pimozide can be increased when it is combined with Nafamostat.Approved
PindololNafamostat may decrease the antihypertensive activities of Pindolol.Approved
PirarubicinNafamostat may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
PiretanideNafamostat may decrease the diuretic activities of Piretanide.Experimental
PirfenidonePirfenidone may increase the anticoagulant activities of Nafamostat.Investigational
PiroxicamPiroxicam may increase the anticoagulant activities of Nafamostat.Approved, Investigational
PlicamycinNafamostat may decrease the excretion rate of Plicamycin which could result in a higher serum level.Approved, Withdrawn
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Nafamostat.Approved
PractololNafamostat may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Nafamostat.Approved
PrasteroneThe risk or severity of adverse effects can be increased when Nafamostat is combined with Prasterone.Approved, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Nafamostat is combined with dehydroepiandrosterone sulfate.Investigational
PrasugrelPrasugrel may increase the anticoagulant activities of Nafamostat.Approved
PrednicarbateThe risk or severity of adverse effects can be increased when Nafamostat is combined with Prednicarbate.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Nafamostat is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Nafamostat is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Nafamostat is combined with Pregnenolone.Experimental
ProbenecidThe serum concentration of Nafamostat can be increased when it is combined with Probenecid.Approved
ProgesteroneThe therapeutic efficacy of Nafamostat can be decreased when used in combination with Progesterone.Approved, Vet Approved
PromestrienePromestriene may decrease the anticoagulant activities of Nafamostat.Investigational
PropacetamolPropacetamol may increase the anticoagulant activities of Nafamostat.Approved
PropranololNafamostat may decrease the antihypertensive activities of Propranolol.Approved, Investigational
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Nafamostat.Experimental
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Nafamostat.Experimental
Protein S humanNafamostat may increase the anticoagulant activities of Protein S human.Approved
ProtriptylineThe serum concentration of Protriptyline can be increased when it is combined with Nafamostat.Approved
PrulifloxacinNafamostat may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PTC299PTC299 may increase the anticoagulant activities of Nafamostat.Investigational
PuromycinNafamostat may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Nafamostat.Approved, Investigational
QuinestrolQuinestrol may decrease the anticoagulant activities of Nafamostat.Approved
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Nafamostat.Approved
RamatrobanRamatroban may increase the anticoagulant activities of Nafamostat.Investigational
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Nafamostat.Approved
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Nafamostat.Approved
ResveratrolResveratrol may increase the anticoagulant activities of Nafamostat.Experimental, Investigational
ReteplaseReteplase may increase the anticoagulant activities of Nafamostat.Approved
ReviparinNafamostat may increase the anticoagulant activities of Reviparin.Approved
RibostamycinNafamostat may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
RidogrelRidogrel may increase the anticoagulant activities of Nafamostat.Approved
RimexoloneThe risk or severity of adverse effects can be increased when Nafamostat is combined with Rimexolone.Approved
RindopepimutThe risk or severity of adverse effects can be increased when Nafamostat is combined with CDX-110.Investigational
RiociguatThe serum concentration of Riociguat can be increased when it is combined with Nafamostat.Approved
RisedronateThe risk or severity of adverse effects can be increased when Nafamostat is combined with Risedronate.Approved, Investigational
RivaroxabanNafamostat may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Nafamostat is combined with Rofecoxib.Investigational, Withdrawn
RoflumilastRoflumilast may increase the immunosuppressive activities of Nafamostat.Approved
RosiglitazoneRosiglitazone may increase the anticoagulant activities of Nafamostat.Approved, Investigational
RosoxacinNafamostat may increase the neuroexcitatory activities of Rosoxacin.Approved
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Nafamostat.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Nafamostat.Approved
SalicylamideSalicylamide may increase the anticoagulant activities of Nafamostat.Approved
Salicylic acidSalicylic acid may increase the anticoagulant activities of Nafamostat.Approved, Vet Approved
SalsalateSalsalate may increase the anticoagulant activities of Nafamostat.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Nafamostat.Experimental
SecoisolariciresinolSecoisolariciresinol may decrease the anticoagulant activities of Nafamostat.Investigational
SelexipagSelexipag may increase the anticoagulant activities of Nafamostat.Approved
SeratrodastSeratrodast may increase the anticoagulant activities of Nafamostat.Approved
SevofluraneSevoflurane may increase the anticoagulant activities of Nafamostat.Approved, Vet Approved
SildenafilThe serum concentration of Sildenafil can be increased when it is combined with Nafamostat.Approved, Investigational
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Nafamostat.Approved
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Nafamostat.Approved
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Nafamostat.Approved
SisomicinNafamostat may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SotalolNafamostat may decrease the antihypertensive activities of Sotalol.Approved
SP1049CNafamostat may decrease the excretion rate of SP1049C which could result in a higher serum level.Investigational
SparfloxacinNafamostat may increase the neuroexcitatory activities of Sparfloxacin.Approved
SpectinomycinNafamostat may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Vet Approved
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Nafamostat.Approved
SpironolactoneNafamostat may decrease the antihypertensive activities of Spironolactone.Approved
SRP 299The risk or severity of adverse effects can be increased when Nafamostat is combined with SRP 299.Investigational
SRT501SRT501 may increase the anticoagulant activities of Nafamostat.Investigational
St. John's WortThe metabolism of Nafamostat can be increased when combined with St. John's Wort.Nutraceutical
StreptokinaseStreptokinase may increase the anticoagulant activities of Nafamostat.Approved
StreptomycinNafamostat may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
StreptozocinNafamostat may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved
SugammadexSugammadex may increase the anticoagulant activities of Nafamostat.Approved
SulfasalazineNafamostat may increase the nephrotoxic activities of Sulfasalazine.Approved
SulindacSulindac may increase the anticoagulant activities of Nafamostat.Approved
SulodexideNafamostat may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Nafamostat.Investigational
SuprofenSuprofen may increase the anticoagulant activities of Nafamostat.Approved, Withdrawn
Synthetic Conjugated Estrogens, AThe serum concentration of Synthetic Conjugated Estrogens, A can be decreased when it is combined with Nafamostat.Approved
Synthetic Conjugated Estrogens, BSynthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Nafamostat.Approved
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Nafamostat.Approved, Investigational
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Nafamostat.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Nafamostat.Approved
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Nafamostat.Approved
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Nafamostat.Approved
Technetium Tc-99m medronateThe risk or severity of adverse effects can be increased when Nafamostat is combined with Technetium Tc-99m Medronate.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Nafamostat.Approved, Investigational
TemafloxacinNafamostat may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Nafamostat.Experimental, Investigational
TemsirolimusThe risk or severity of adverse effects can be increased when Nafamostat is combined with Temsirolimus.Approved
TenecteplaseTenecteplase may increase the anticoagulant activities of Nafamostat.Approved
Tenofovir disoproxilThe risk or severity of adverse effects can be increased when Nafamostat is combined with Tenofovir.Approved, Investigational
TenoxicamTenoxicam may increase the anticoagulant activities of Nafamostat.Approved
TeriflunomideTeriflunomide may increase the anticoagulant activities of Nafamostat.Approved
TesmilifeneTesmilifene may increase the anticoagulant activities of Nafamostat.Investigational
TheophyllineThe serum concentration of Theophylline can be decreased when it is combined with Nafamostat.Approved
TianeptineThe serum concentration of Tianeptine can be increased when it is combined with Nafamostat.Approved
Tiaprofenic acidTiaprofenic acid may increase the anticoagulant activities of Nafamostat.Approved
TiboloneTibolone may increase the anticoagulant activities of Nafamostat.Approved
TicagrelorTicagrelor may increase the anticoagulant activities of Nafamostat.Approved
TiclopidineTiclopidine may increase the anticoagulant activities of Nafamostat.Approved
Tiludronic acidThe risk or severity of adverse effects can be increased when Nafamostat is combined with Tiludronate.Approved, Vet Approved
TimololNafamostat may decrease the antihypertensive activities of Timolol.Approved
TinoridineTinoridine may increase the anticoagulant activities of Nafamostat.Investigational
TinzaparinTinzaparin may increase the anticoagulant activities of Nafamostat.Approved
TipranavirThe serum concentration of Nafamostat can be decreased when it is combined with Tipranavir.Approved, Investigational
TirofibanTirofiban may increase the anticoagulant activities of Nafamostat.Approved
TixocortolThe risk or severity of adverse effects can be increased when Nafamostat is combined with Tixocortol.Approved
TobramycinNafamostat may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
TofacitinibNafamostat may increase the immunosuppressive activities of Tofacitinib.Approved, Investigational
Tolfenamic AcidTolfenamic Acid may increase the anticoagulant activities of Nafamostat.Approved
TolmetinTolmetin may increase the anticoagulant activities of Nafamostat.Approved
TorasemideNafamostat may decrease the diuretic activities of Torasemide.Approved
TositumomabThe risk or severity of adverse effects can be increased when Nafamostat is combined with Tositumomab.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Nafamostat.Approved
TranilastTranilast may increase the anticoagulant activities of Nafamostat.Approved, Investigational
TrapidilTrapidil may increase the anticoagulant activities of Nafamostat.Approved
TrastuzumabTrastuzumab may increase the neutropenic activities of Nafamostat.Approved, Investigational
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Nafamostat.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Nafamostat.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Nafamostat is combined with Triamcinolone.Approved, Vet Approved
TriamtereneNafamostat may decrease the antihypertensive activities of Triamterene.Approved
TriazolamThe serum concentration of Triazolam can be increased when it is combined with Nafamostat.Approved
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Nafamostat.Approved, Vet Approved
TriflusalTriflusal may increase the anticoagulant activities of Nafamostat.Approved
TrimipramineThe serum concentration of Trimipramine can be increased when it is combined with Nafamostat.Approved
TrovafloxacinNafamostat may increase the neuroexcitatory activities of Trovafloxacin.Approved, Withdrawn
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Nafamostat.Approved
UrokinaseUrokinase may increase the anticoagulant activities of Nafamostat.Approved, Investigational, Withdrawn
ValdecoxibThe risk or severity of adverse effects can be increased when Nafamostat is combined with Valdecoxib.Investigational, Withdrawn
Valproic AcidThe serum concentration of Valproic Acid can be decreased when it is combined with Nafamostat.Approved, Investigational
ValrubicinNafamostat may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Nafamostat.Approved, Investigational
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Nafamostat.Approved
VerapamilThe metabolism of Verapamil can be decreased when combined with Nafamostat.Approved
Vitamin EVitamin E may increase the anticoagulant activities of Nafamostat.Approved, Nutraceutical, Vet Approved
VorapaxarThe risk or severity of adverse effects can be increased when Vorapaxar is combined with Nafamostat.Approved
WarfarinNafamostat may increase the anticoagulant activities of Warfarin.Approved
XimelagatranNafamostat may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
ZaltoprofenZaltoprofen may increase the anticoagulant activities of Nafamostat.Approved
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with Nafamostat.Approved
ZileutonZileuton may increase the anticoagulant activities of Nafamostat.Approved, Investigational, Withdrawn
Zoledronic acidThe risk or severity of adverse effects can be increased when Nafamostat is combined with Zoledronic acid.Approved
ZomepiracZomepirac may increase the anticoagulant activities of Nafamostat.Withdrawn
ZorubicinNafamostat may decrease the excretion rate of Zorubicin which could result in a higher serum level.Experimental
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General References
  1. Maruyama Y, Yoshida H, Uchino S, Yokoyama K, Yamamoto H, Takinami M, Hosoya T: Nafamostat mesilate as an anticoagulant during continuous veno-venous hemodialysis: a three-year retrospective cohort study. Int J Artif Organs. 2011 Jul;34(7):571-6. doi: 10.5301/IJAO.2011.8535. [PubMed:21786254 ]
  2. Kang MW, Song HJ, Kang SK, Kim Y, Jung SB, Jee S, Moon JY, Suh KS, Lee SD, Jeon BH, Kim CS: Nafamostat Mesilate Inhibits TNF-alpha-Induced Vascular Endothelial Cell Dysfunction by Inhibiting Reactive Oxygen Species Production. Korean J Physiol Pharmacol. 2015 May;19(3):229-34. doi: 10.4196/kjpp.2015.19.3.229. Epub 2015 Apr 30. [PubMed:25954127 ]
  3. Choi S, Kwon HJ, Song HJ, Choi SW, Nagar H, Piao S, Jung SB, Jeon BH, Kim DW, Kim CS: Nafamostat mesilate promotes endothelium-dependent vasorelaxation via the Akt-eNOS dependent pathway. Korean J Physiol Pharmacol. 2016 Sep;20(5):539-45. doi: 10.4196/kjpp.2016.20.5.539. Epub 2016 Aug 26. [PubMed:27610041 ]
  4. Choi JY, Kang YJ, Jang HM, Jung HY, Cho JH, Park SH, Kim YL, Kim CD: Nafamostat Mesilate as an Anticoagulant During Continuous Renal Replacement Therapy in Patients With High Bleeding Risk: A Randomized Clinical Trial. Medicine (Baltimore). 2015 Dec;94(52):e2392. doi: 10.1097/MD.0000000000002392. [PubMed:26717390 ]
  5. Chen T, Wang J, Li C, Zhang W, Zhang L, An L, Pang T, Shi X, Liao H: Nafamostat mesilate attenuates neuronal damage in a rat model of transient focal cerebral ischemia through thrombin inhibition. Sci Rep. 2014 Jul 2;4:5531. doi: 10.1038/srep05531. [PubMed:24985053 ]
  6. Kim HS, Lee KE, Oh JH, Jung CS, Choi D, Kim Y, Jeon JS, Han DC, Noh H: Cardiac arrest caused by nafamostat mesilate. Kidney Res Clin Pract. 2016 Sep;35(3):187-9. doi: 10.1016/j.krcp.2015.10.003. Epub 2015 Nov 12. [PubMed:27668164 ]
  7. Muto S, Imai M, Asano Y: Mechanisms of the hyperkalaemia caused by nafamostat mesilate: effects of its two metabolites on Na+ and K+ transport properties in the rabbit cortical collecting duct. Br J Pharmacol. 1994 Jan;111(1):173-8. [PubMed:8012693 ]
  8. FDA Executive Summary [Link]
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (29.4 KB)
Clinical Trials
Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedPreventionPostreperfusion Syndrome / Transplantation, Liver1
4CompletedTreatmentAcute Kidney Injury (AKI)2
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.0341 mg/mLALOGPS
logP1.91ALOGPS
logP2.52ChemAxon
logS-4ALOGPS
pKa (Strongest Basic)11.32ChemAxon
Physiological Charge2ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count5ChemAxon
Polar Surface Area138.07 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity122.12 m3·mol-1ChemAxon
Polarizability37.5 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET featuresNot Available
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as guanidinobenzoic acids and derivatives. These are aromatic compounds containing a guanidine group linked to the benzene ring of a benzoic acid (or a derivative thereof).
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassBenzoic acids and derivatives
Direct ParentGuanidinobenzoic acids and derivatives
Alternative ParentsNaphthalenes / Benzoic acid esters / Benzoyl derivatives / Guanidines / Carboxylic acid esters / Propargyl-type 1,3-dipolar organic compounds / Monocarboxylic acids and derivatives / Carboximidamides / Carboxamidines / Organopnictogen compounds
SubstituentsGuanidinobenzoic acid or derivatives / Benzoate ester / Naphthalene / Benzoyl / Carboxylic acid ester / Guanidine / Amidine / Carboxylic acid amidine / Carboxylic acid derivative / Monocarboxylic acid or derivatives
Molecular FrameworkAromatic homopolycyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Thrombospondin receptor activity
Specific Function:
Thrombin, which cleaves bonds after Arg and Lys, converts fibrinogen to fibrin and activates factors V, VII, VIII, XIII, and, in complex with thrombomodulin, protein C. Functions in blood homeostasis, inflammation and wound healing.
Gene Name:
F2
Uniprot ID:
P00734
Uniprot Name:
Prothrombin
Molecular Weight:
70036.295 Da
References
  1. Iwaki M, Ino Y, Motoyoshi A, Ozeki M, Sato T, Kurumi M, Aoyama T: Pharmacological studies of FUT-175, nafamostat mesilate. V. Effects on the pancreatic enzymes and experimental acute pancreatitis in rats. Jpn J Pharmacol. 1986 Jun;41(2):155-62. [PubMed:2427760 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Serine-type endopeptidase activity
Specific Function:
Factor Xa is a vitamin K-dependent glycoprotein that converts prothrombin to thrombin in the presence of factor Va, calcium and phospholipid during blood clotting.
Gene Name:
F10
Uniprot ID:
P00742
Uniprot Name:
Coagulation factor X
Molecular Weight:
54731.255 Da
References
  1. Baek NN, Jang HR, Huh W, Kim YG, Kim DJ, Oh HY, Lee JE: The role of nafamostat mesylate in continuous renal replacement therapy among patients at high risk of bleeding. Ren Fail. 2012;34(3):279-85. doi: 10.3109/0886022X.2011.647293. Epub 2012 Jan 17. [PubMed:22251267 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Serine-type endopeptidase activity
Specific Function:
Factor XII is a serum glycoprotein that participates in the initiation of blood coagulation, fibrinolysis, and the generation of bradykinin and angiotensin. Prekallikrein is cleaved by factor XII to form kallikrein, which then cleaves factor XII first to alpha-factor XIIa and then trypsin cleaves it to beta-factor XIIa. Alpha-factor XIIa activates factor XI to factor XIa.
Gene Name:
F12
Uniprot ID:
P00748
Uniprot Name:
Coagulation factor XII
Molecular Weight:
67791.53 Da
References
  1. Baek NN, Jang HR, Huh W, Kim YG, Kim DJ, Oh HY, Lee JE: The role of nafamostat mesylate in continuous renal replacement therapy among patients at high risk of bleeding. Ren Fail. 2012;34(3):279-85. doi: 10.3109/0886022X.2011.647293. Epub 2012 Jan 17. [PubMed:22251267 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Serine-type endopeptidase activity
Specific Function:
Has activity against the synthetic substrates Boc-Phe-Ser-Arg-Mec, Boc-Leu-Thr-Arg-Mec, Boc-Gln-Ala-Arg-Mec and Boc-Val-Pro-Arg-Mec. The single-chain form is more active than the two-chain form against all of these substrates.
Gene Name:
PRSS1
Uniprot ID:
P07477
Uniprot Name:
Trypsin-1
Molecular Weight:
26557.88 Da
References
  1. Ramjee MK, Henderson IM, McLoughlin SB, Padova A: The kinetic and structural characterization of the reaction of nafamostat with bovine pancreatic trypsin. Thromb Res. 2000 Jun 15;98(6):559-69. [PubMed:10899355 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Serine-type endopeptidase activity
Specific Function:
Glandular kallikreins cleave Met-Lys and Arg-Ser bonds in kininogen to release Lys-bradykinin.
Gene Name:
KLK1
Uniprot ID:
P06870
Uniprot Name:
Kallikrein-1
Molecular Weight:
28889.425 Da
References
  1. Iwaki M, Ino Y, Motoyoshi A, Ozeki M, Sato T, Kurumi M, Aoyama T: Pharmacological studies of FUT-175, nafamostat mesilate. V. Effects on the pancreatic enzymes and experimental acute pancreatitis in rats. Jpn J Pharmacol. 1986 Jun;41(2):155-62. [PubMed:2427760 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Virus receptor activity
Specific Function:
ICAM proteins are ligands for the leukocyte adhesion protein LFA-1 (integrin alpha-L/beta-2). During leukocyte trans-endothelial migration, ICAM1 engagement promotes the assembly of endothelial apical cups through ARHGEF26/SGEF and RHOG activation.(Microbial infection) Acts as a receptor for major receptor group rhinovirus A-B capsid proteins (PubMed:1968231, PubMed:2538243). Acts as a receptor...
Gene Name:
ICAM1
Uniprot ID:
P05362
Uniprot Name:
Intercellular adhesion molecule 1
Molecular Weight:
57824.785 Da
References
  1. Kang MW, Song HJ, Kang SK, Kim Y, Jung SB, Jee S, Moon JY, Suh KS, Lee SD, Jeon BH, Kim CS: Nafamostat Mesilate Inhibits TNF-alpha-Induced Vascular Endothelial Cell Dysfunction by Inhibiting Reactive Oxygen Species Production. Korean J Physiol Pharmacol. 2015 May;19(3):229-34. doi: 10.4196/kjpp.2015.19.3.229. Epub 2015 Apr 30. [PubMed:25954127 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Secondary active organic cation transmembrane transporter activity
Specific Function:
Translocates a broad array of organic cations with various structures and molecular weights including the model compounds 1-methyl-4-phenylpyridinium (MPP), tetraethylammonium (TEA), N-1-methylnicotinamide (NMN), 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP), the endogenous compounds choline, guanidine, histamine, epinephrine, adrenaline, noradrenaline and dopamine, and the drugs quinine...
Gene Name:
SLC22A1
Uniprot ID:
O15245
Uniprot Name:
Solute carrier family 22 member 1
Molecular Weight:
61153.345 Da
References
  1. Li Q, Sai Y, Kato Y, Muraoka H, Tamai I, Tsuji A: Transporter-mediated renal handling of nafamostat mesilate. J Pharm Sci. 2004 Feb;93(2):262-72. [PubMed:14705184 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Quaternary ammonium group transmembrane transporter activity
Specific Function:
Mediates tubular uptake of organic compounds from circulation. Mediates the influx of agmatine, dopamine, noradrenaline (norepinephrine), serotonin, choline, famotidine, ranitidine, histamin, creatinine, amantadine, memantine, acriflavine, 4-[4-(dimethylamino)-styryl]-N-methylpyridinium ASP, amiloride, metformin, N-1-methylnicotinamide (NMN), tetraethylammonium (TEA), 1-methyl-4-phenylpyridiniu...
Gene Name:
SLC22A2
Uniprot ID:
O15244
Uniprot Name:
Solute carrier family 22 member 2
Molecular Weight:
62579.99 Da
References
  1. Li Q, Sai Y, Kato Y, Muraoka H, Tamai I, Tsuji A: Transporter-mediated renal handling of nafamostat mesilate. J Pharm Sci. 2004 Feb;93(2):262-72. [PubMed:14705184 ]
Drug created on October 20, 2016 17:07 / Updated on August 02, 2017 17:46